PolyneuropathiesDiabetic Complications NeurologicalDiabetes Mellitus Type 2
Study summary
Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
Eligibility
Sex
ALL
Min age
30 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Age between 30 and 75 years
* Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)
* Ability to understand and sign informed consent
* Willingness to participate in the study
Exclusion Criteria:
* Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)
* Chronic kidney disease (eGFR \<60 mL/min/1.73 m²)
* Active infection
* Myopathies or other muscle diseases
* Central nervous system diseases (e.g., stroke, Parkinson disease)
* Severe orthopedic conditions impairing mobility
* Inability or unwillingness to provide informed consent
Primary outcome measure(s)
Serum Irisin Concentration — Baseline Serum irisin concentration (ng/mL) will be measured from fasting venous blood samples using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Serum irisin concentrations will be compared among participants with diabetic polyneuropathy (DPN+), participants with Type 2 Diabetes Mellitus without diabetic polyneuropathy (DPN-), and healthy control participants. The primary objective is to evaluate whether serum irisin concentration may serve as a biomarker for diabetic polyneuropathy..
Trial sites (1)
Facility
City
Region
Status
Kanuni Sultan Süleyman Training and Research Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.